Compositions and methods for treating cancer

1. A K-Ras protein covalently bonded to a compound, wherein the compound is covalently bonded to cysteine residue 12 of the K-Ras protein and is in contact with one or more amino acid residues of a K-Ras protein Switch 2 binding pocket.

2. The K-Ras protein of claim 1 , wherein the one or more amino acid residues of the K-Ras protein Switch 2 binding pocket are selected from the group consisting of V7, V9, G10, K16, P34, T58, G60, Q61, E62, E63, R68, Y71, M72, Y96, Q99, and I100.

3. The K-Ras protein of claim 1 , wherein the one or more amino acid residues of the K-Ras protein Switch 2 binding pocket comprise at least three amino acid residues selected from the group consisting of V7, V9, G10, K16, P34, T58, G60, Q61, E62, E63, R68, Y71, M72, Y96, Q99, and I100.

4. The K-Ras protein of claim 1 , wherein the one or more amino acid residues of the K-Ras protein Switch 2 binding pocket are selected from the group consisting of K16, R68, M72, Y96, and Q99.

5. The K-Ras protein of claim 1 , wherein the compound has an electrophilic chemical moiety covalently bonded to cysteine residue 12 of the K-Ras protein, wherein the electrophilic chemical moiety is a substituted or unsubstituted acrylamide.

6. The K-Ras protein of claim 1 , wherein the compound has an electrophilic chemical moiety covalently bonded to cysteine residue 12 of the K-Ras protein, wherein electrophilic chemical moiety is:

wherein R 13 is hydrogen, halogen, —CX b 3 , or —CN; and X b is Cl, Br, I or F.

7. The K-Ras protein of claim 1 , wherein the compound has the formula:

R 1 -L 1 -L 2 -L 3 -E,

wherein:

R 1 is a Switch 2 Binding Pocket binding moiety;

L 1 is a bond or a divalent radical chemical linker;

L 2 is a bond;

L 3 is

f8 is an integer from 0 to 8;

R 2C is independently hydrogen or substituted or unsubstituted alkyl; and

E is an electrophilic chemical moiety covalently bonded with cysteine residue 12 of the K-Ras protein.

8. The K-Ras protein of claim 7 , wherein E is:

wherein R 13 is hydrogen, halogen, —CX b 3 , or —CN; and X b is Cl, Br, I or F.

9. The K-Ras protein of claim 7 , wherein:

R 1 is R 3 — substituted or unsubstituted aryl or R 3 -substituted or unsubstituted heteroaryl;

R 3 is independently hydrogen, oxo, halogen, —CX 3 , —CN, —SO 2 Cl, —SO n R 10 , —SO v NR 7 R 8 , —NHNH 2 , —ONR 7 R 8 , —NHC═(O)NHNH 2 , —NHC═(O)NR 7 R 8 , —N(O) m , —NR 7 R 8 , —C(O)R 9 , —C(O)—OR 9 , —C(O)NR 7 R 8 , —NR 7 SO 2 R 10 , —NR 7 C═(O)R 9 , —NR 7 C(O)—OR 9 , —NR 7 OR 9 , —OCX 3 , —OCHX 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 7 , R 8 , R 9 , and R 10 are independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 2 Cl, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC═(O)NHNH 2 , —NHC═(O)NH 2 , —NHSO 2 H, —NHC═(O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCHF 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

m and v are independently 1 or 2;

n is independently an integer from 0 to 4; and

each X is independently —Cl, —Br, —I, or —F.

10. The K-Ras protein of claim 9 , wherein

R 1 is R 3 -substituted or unsubstituted aryl;

R 3 is independently oxo, halogen, —OR 10 , substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

R 10 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted alkyl.